Product Description
Ad5 [E1-, E2b-]-MUC1. NANT Pancreatic Cancer Vaccine (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03586869)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: ImmunityBio
Company Location: SAN DIEGO CA 92121
Company CEO: Richard Adcock
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Triple Negative Breast Cancer|Non-Small-Cell Lung Cancer|Hepatocellular Carcinoma|Lymphoma, Non-Hodgkin|Ovarian Cancer|Colorectal Cancer|Carcinoma, Merkel Cell|Squamous Cell Carcinoma|Head and Neck Cancer|Pancreatic Cancer|Chordoma|Melanoma|Transitional Cell Carcinoma
Phase 1: Prostate Cancer|Colorectal Cancer|Lung Cancer|Breast Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| QUILT-3.067 | P2 |
Terminated |
Triple Negative Breast Cancer |
2020-09-11 |
|
| QUILT-3.091 | P2 |
Withdrawn |
Chordoma |
2020-08-31 |
56% |
| QUILT-3.091 | P2 |
Withdrawn |
Chordoma |
2020-08-31 |
56% |
| QUILT-3.091 | P2 |
Withdrawn |
Chordoma |
2020-08-31 |
56% |
| QUILT-3.091 | P2 |
Withdrawn |
Chordoma |
2020-08-31 |
56% |
| TNBC | P2 |
Withdrawn |
Triple Negative Breast Cancer |
2020-06-01 |
31% |
| TNBC | P2 |
Withdrawn |
Triple Negative Breast Cancer |
2020-06-01 |
31% |
| TNBC | P2 |
Withdrawn |
Triple Negative Breast Cancer |
2020-06-01 |
31% |
| TNBC | P2 |
Withdrawn |
Triple Negative Breast Cancer |
2020-06-01 |
31% |
| TNBC | P2 |
Withdrawn |
Triple Negative Breast Cancer |
2020-06-01 |
31% |
| 18-C-0073 | P1 |
Completed |
Prostate Cancer |
2020-01-15 |